Jarden Sticks to Its Buy Rating for Integral Diagnostics Ltd. (IDX)
Jarden Adjusts Integral Diagnostics' Price Target to AU$3.68 From AU$3.72, Keeps at Buy
Integral Diagnostics Ltd. (IDX) Receives a Hold From Canaccord Genuity
Integral Diagnostics Price Target Raised 10% to A$3.30/Share by Ord Minnett
Ord Minnett Sticks to Their Buy Rating for Integral Diagnostics Ltd. (IDX)
Integral Diagnostics Raised to Overweight From Mkt Weight by Wilsons >IDX.AU
Morgan Stanley Adjusts Integral Diagnostics' Price Target to AU$1.85 From AU$1.70, Keeps at Underweight
Jarden Research Adjusts Integral Diagnostics' Price Target to AU$2.59 From AU$2.54, Keeps at Neutral
Analysts Offer Insights on Healthcare Companies: Integral Diagnostics Ltd. (AU:IDX), Biophytis SA (Stuttgart: DE:6XB) and Merck KGaA (GB:0O14)